Estrella Immunopharma, Inc. financial data

Symbol
ESLA, ESLAW on Nasdaq
Location
Emeryville, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 21% % -97%
Debt-to-equity -169% % -1126%
Return On Equity -156% % -191%
Return On Assets -134% % -125%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37,765,589 shares 4.4%
Common Stock, Shares, Outstanding 37,765,589 shares
Entity Public Float $39,971,984 USD
Common Stock, Value, Issued $3,828 USD 4.6%
Weighted Average Number of Shares Outstanding, Basic 37,096,024 shares 2.5%
Weighted Average Number of Shares Outstanding, Diluted 37,096,024 shares 2.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $4,152,642 USD 47%
General and Administrative Expense $648,507 USD 18%
Operating Income (Loss) $4,801,149 USD -42%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $4,801,149 USD -42%
Income Tax Expense (Benefit) $850 USD -48%
Net Income (Loss) Attributable to Parent $4,801,149 USD -42%
Earnings Per Share, Basic -0.13 USD/shares -44%
Earnings Per Share, Diluted -0.13 USD/shares -44%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,626,610 USD -9.5%
Assets, Current $2,023,511 USD -9.5%
Operating Lease, Right-of-Use Asset $0 USD
Assets $3,523,511 USD -5.7%
Accrued Liabilities, Current $166,941 USD
Liabilities, Current $13,359,934 USD 347%
Liabilities $13,359,934 USD 347%
Retained Earnings (Accumulated Deficit) $36,377,641 USD -59%
Stockholders' Equity Attributable to Parent $9,836,423 USD -1418%
Liabilities and Equity $3,523,511 USD -5.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $465,981 USD 89%
Net Cash Provided by (Used in) Financing Activities $29,462 USD 65%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 38,280,870 shares 4.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,626,610 USD -9.5%
Deferred Tax Assets, Valuation Allowance $5,403,415 USD
Deferred Tax Assets, Gross $5,403,415 USD
Deferred Tax Assets, Operating Loss Carryforwards $2,425,707 USD
Additional Paid in Capital $27,135,769 USD 12%
Share-based Payment Arrangement, Expense $152,421 USD